First report of t(5;11) KMT2A-MAML1 fusion in de novo infant acute lymphoblastic leukemia.


Journal

Cancer genetics
ISSN: 2210-7762
Titre abrégé: Cancer Genet
Pays: United States
ID NLM: 101539150

Informations de publication

Date de publication:
10 2020
Historique:
received: 03 04 2020
revised: 16 09 2020
accepted: 20 09 2020
pubmed: 30 9 2020
medline: 1 1 2021
entrez: 29 9 2020
Statut: ppublish

Résumé

Infant acute lymphoblastic leukemia (ALL) comprises 2.5%-5% of pediatric ALL with inferior survival compared to older children. A majority of infants (80%) with ALL harbor KMT2A gene rearrangement, which portends a poor prognosis. Approximately 94 different partner genes have been identified to date. The common rearrangements include t(4;11)(q21;q23)KMT2A-AFF1,t(11;19) (q23;p13.3)KMT2A-MLLT1 and t(9;11)(p22;q23)KMT2A-MLLT3. We report a novel translocation t(5;11)(q35;q23)KMT2A-MAML1 in newly diagnosed infant precursor B-ALL. Long-term follow-up and a larger number of patients are needed to better understand its prognostic significance.

Identifiants

pubmed: 32992102
pii: S2210-7762(20)30273-8
doi: 10.1016/j.cancergen.2020.09.004
pii:
doi:

Substances chimiques

DNA-Binding Proteins 0
KMT2A protein, human 0
MAML1 protein, human 0
Oncogene Proteins, Fusion 0
Transcription Factors 0
Myeloid-Lymphoid Leukemia Protein 149025-06-9
Histone-Lysine N-Methyltransferase EC 2.1.1.43

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

31-33

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Sneha Tandon (S)

Division of Hematology and Oncology, University Hospital Southampton, United Kingdom. Electronic address: Sneha.tandon@uhs.nhs.uk.

Mary Shago (M)

The Department of Pediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Canada; Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Canada.

Scott Davidson (S)

Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Canada.

Nisha Kanwar (N)

Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Canada.

Fabio Fuligni (F)

Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Canada.

Adam Shlien (A)

The Department of Pediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Canada; Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Canada.

James Whitlock (J)

Division of Pediatrics Hematology/Oncology, The Hospital for Sick Children; Department of Pediatrics, University of Toronto, Toronto, Canada.

Anita Villani (A)

Division of Pediatrics Hematology/Oncology, The Hospital for Sick Children; Department of Pediatrics, University of Toronto, Toronto, Canada.

Oussama Abla (O)

Division of Pediatrics Hematology/Oncology, The Hospital for Sick Children; Department of Pediatrics, University of Toronto, Toronto, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH